BCIQ Profiles

Company Profile Report

Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes

Read the full 220 word article

How to gain access

Continue reading with a
two-week free trial.